Objective: This study aimed to assess the efficacy, safety, and patient satisfaction regarding semaglutide treatment among the population of Qassim, Saudi Arabia.
Methodology: A self-administered questionnaire was distributed through online platforms to collect data from patients with type-2 diabetes who were using semaglutide treatment for 2-3 years in Qassim region, Saudi Arabia.
Results: Around 56.5% of the study participants had a subcutaneous form of semaglutide treatment. Before the treatment, 54.0% of the participants on oral semaglutide were above normal weight, and 47.8% of participants on subcutaneous semaglutide were above normal weight. After the treatment, the oral semaglutide group demonstrated higher efficacy in reducing weight and improving HbA1c levels in comparison to subcutaneous semaglutide. Most of the study participants were satisfied with their treatment; however, the oral semaglutide group demonstrated higher satisfaction than the subcutaneous group. Adverse events such as nausea, vomiting, and diarrhea, in addition to headaches and dizziness, were all higher among the subcutaneous semaglutide group and it demonstrated a statistically significant association with the patient’s possibility of changing their treatment form.
Conclusion: Semaglutide treatment was effective, safe and had an overall high satisfaction rate among type-2 diabetic patients in the Qassim region, of Saudi Arabia.
Key words: Semaglutide, GLP-1 antagonists, Type 2 diabetes, Qassim region, gastrointestinal
|
